On Wednesday, Shares of Vereit Inc (NYSE:VER), subtract -3.89% and closed at $9.64 in the last trading session. The last trading range of the stock ranges between $9.64 and $10.13. The company’s Market capitalization is $9.25 Billion with the total Outstanding Shares of 965.19 Million. Laredo Petroleum, Inc. operates as an independent energy company in the United States. It focuses on the acquisition, exploration, and development of oil and natural gas properties, in addition to the transportation of oil and natural gas mainly in the Permian Basin in West Texas. As of December 31, 2015, it had interests in the 135,408 net acres in the Permian Basin; and had total proved reserves of 125,698 thousand barrels of oil equivalent.
Laredo Petroleum Inc (NYSE:LPI), jumped 3.91% and closed at $13.54 in the last trading session. The last trading range of the stock ranges between $13.08 and $13.80. The company’s Market capitalization is $3.26 Billion with the total Outstanding Shares of 240.12 Million. Cameco Corporation produces and sells uranium worldwide. It operates through three segments: Uranium, Fuel Services, and NUKEM. The Uranium segment is involved in the exploration for, mining, and milling, in addition to purchase and sale of uranium concentrates. Its operating uranium properties include the McArthur River/Key Lake, Cigar Lake, and Rabbit Lake properties located in Saskatchewan, Canada; the Inkai property situated in Kazakhstan; and the Smith Ranch-Highland property located in Wyoming, in addition to the Crow Butte property situated in Nebraska, the United States. The Fuel Services segment provides refining, conversion, and uranium fuel manufacturing services. Its products include uranium trioxide, uranium hexafluoride, and uranium dioxide. This segment also manufactures and sells fuel bundles and reactor components for CANDU reactors. The NUKEM segment trades in uranium and uranium-related products.
Depomed Inc (NASDAQ:DEPO), jumped 2.56% and closed at $26.01 in the last trading session. The last trading range of the stock ranges between $25.49 and $26.50. During the 52-week trading session the minimum price at which share price traded, registered at $12.25 and reached to max level of $27.02. Depomed, Inc. (DEPO) recently declared that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in favor of Depomed in the company’s patent litigation against all three filers of Abbreviated New Drug Applications (ANDAs) for Depomed’s NUCYNTA franchise. With the court’s ruling, Depomed anticipates market exclusivity until December 2025 for NUCYNTA® ER, NUCYNTA® and NUCYNTA® oral solution (an unmarketed form of NUCYNTA). 1
“We are happy with the Court’s decision as it confirms the validity and strength of the NUCYNTA patents,” said Jim Schoeneck, President and CEO of Depomed. “We look forward to growing the NUCYNTA franchise, comprised of two important and highly-differentiated medicines, for at least the next 9 years.”
The court found U.S. patent Nos. 7,994,364 and RE39,593 to be valid and infringed by the defendants. The patents cover the entire NUCYNTA franchise and will expire on December 27, 2025 and February 5, 2023, respectively.1 Judge Cecchi upheld the validity of U.S. Patent No. 8,536,130 (the “130 Patent”), but found that two of the three filers do not infringe the patent. The ‘130 Patent covers NUCYNTA ER until March 2029. 1 The company intends to appeal the court’s finding as it relates to infringement of the ‘130 Patent.